Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMar 28, 2014	Xencor Showcases Bispecific Antibody Programs at Annual Summit on Practical and Emerging Trends in Multiple Myeloma MONROVIA, Calif. , March 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today presented an overview of its bispecific	View HTML Xencor Showcases Bispecific Antibody Programs at Annual Summit on Practical and Emerging Trends in Multiple Myeloma 16.5 KB
Toggle SummaryFeb 05, 2019	Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech -- Xencor Receives $120 Million Upfront Payment, up to $180 Million in Development Milestones Per Program and Profit Share from Commercialized Medicines MONROVIA, Calif. , Feb. 5, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered	View HTML PDF Version
Toggle SummaryJun 14, 2016	Xencor to Host Analyst Day and Webcast on June 28, 2016 MONROVIA, Calif. , June 14, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the Company will host an	View HTML Xencor to Host Analyst Day and Webcast on June 28, 2016 18.2 KB
Toggle SummaryMay 07, 2014	Xencor to Host First Quarter 2014 Financial Results Webcast and Conference Call MONROVIA, Calif. , May 7, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter	View HTML Xencor to Host First Quarter 2014 Financial Results Webcast and Conference Call 12.7 KB
Toggle SummaryApr 28, 2015	Xencor to Host First Quarter 2015 Financial Results Webcast and Conference Call on May 4, 2015 MONROVIA, Calif. , April 28, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter 2015	View HTML Xencor to Host First Quarter 2015 Financial Results Webcast and Conference Call on May 4, 2015 15.9 KB
Toggle SummaryApr 25, 2016	Xencor to Host First Quarter 2016 Financial Results Webcast and Conference Call on May 2, 2016 MONROVIA, Calif. , April 25, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter	View HTML Xencor to Host First Quarter 2016 Financial Results Webcast and Conference Call on May 2, 2016 15.9 KB
Toggle SummaryMay 02, 2017	Xencor to Host First Quarter 2017 Financial Results Webcast and Conference Call on May 9, 2017 MONROVIA, Calif. , May 2, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release first quarter 2017	View HTML Xencor to Host First Quarter 2017 Financial Results Webcast and Conference Call on May 9, 2017 14.1 KB
Toggle SummaryApr 30, 2018	Xencor to Host First Quarter 2018 Financial Results Webcast and Conference Call on May 7, 2018 MONROVIA, Calif. , April 30, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release first quarter	View HTML PDF Version
Toggle SummaryMay 02, 2019	Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019 MONROVIA, Calif. --(BUSINESS WIRE)--May 2, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release first quarter	View HTML PDF Version
Toggle SummaryApr 30, 2020	Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020 MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 30, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release first quarter 2020 financial results after	View HTML PDF Version

Tools

Press Releases